ubmslatePT-logo-ubm

PT Mobile Logo

Search form

Topics:

Thomas R. Kosten, MD

Thomas R. Kosten, MD

Dr Kosten is JH Waggoner Chair and Professor of Psychiatry, Neuroscience, Pharmacology, Immunology & Pathology and Co-Director, Dan Duncan Institute for Clinical and Translational Research at The Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine in Houston, TX. Dr Kosten is also Editor of the American Journal on Addictions, the official journal of the American Academy of Addiction Psychiatry.

Posts by Author

A clinical collection on addiction treatment, ADHD and SUDs, important drug indications, vaping, cannabis use, benzodiazepines, the perils of self-medicating and other topics relevant to practicing psychiatrists.

Significant progress has been made in containing the opioid epidemic, but new threats loom. Thomas Kosten, MD, an addiction psychiatrist, takes a brief look.

The Chair of a Special Report on substance abuse disorders describes the highlights of 6 articles in the series.

© marcos mesa mam Wordley/shutterstock.com

There are no FDA-approved pharmacotherapies for cocaine use disorder. Here: a review of the off-label use of promising medications for this addiction.

A psychiatrist explains the pharmacogenetic factors that suggest a positive—or negative—response to naltrexone. He also offers some practical guidance about using this agent in clinical practice.

Antidrug vaccines represent an exciting area of development in the pharmacological treatment of chemical dependency. In addition to the clinical trials being conducted on vaccines for cocaine and nicotine dependence, preclinical development of vaccines for methamphetamine and heroin is ongoing.

By clicking Accept, you agree to become a member of the UBM Medica Community.